By 2023, the global Malignant ascites treatment market is estimated to grow at a CAGR of 4.0 percent, reaching USD 2,832.5 million

Ascites is a disorder marked by the accumulation of fluid in the abdominal cavity, especially the peritoneal cavity. It occurs when the body's ability to remove fluids is impaired. Malignant peritoneal effusion or malignant ascites are terms used to describe ascites that develops as a result of malignancy. Cancers of the breast, liver, ovary, lungs, lymphoma, and colon are the most prevalent malignancies linked with malignant ascites. Ascites is a condition in which the lymph glands of the body get clogged, causing low blood pressure, sleeplessness, lethargy, and skin problems. 

Abdominal pain or discomfort, shortness of breath, abdominal swelling, leg or ankle edoema, constipation, and weight gain are all common symptoms of malignant ascites.Ultrasound, x-ray tests, CT scans, and physical examination can all be used to diagnose ascites. The survival rate of these patients is extremely low, despite the availability of effective treatments such as paracentesis, chemotherapy, and surgery.Chemotherapy, shunting, paracentesis, and the use of medications like spironolactone and spironolactone are all common treatments for malignant ascites. The most common cause of ascites is liver cirrhosis, however ascites can also be caused by renal failure, heart failure, malignancy, or infection.

By 2023, the Malignant ascites treatment market is estimated to grow at a CAGR of 4.0 percent, reaching USD 2,832.5 million. Ascites is a condition in which fluid builds up abnormally in the abdominal cavity. Cirrhosis of the liver is the most common cause of ascites. Its presence indicates severe portal hypertension. Heart disease and kidney failure are two less common conditions that may lead to the development of ascites.In the course of ovarian cancer, malignant ascites is a common symptom. Cancer-related ascites have also been seen in breast, lung, pancreas, stomach, and liver cancers. Physical examination can diagnose ascites in a volume more than 1.5 litres. Ultrasound and CT scan are suggested for a lower amount of fluid.

Cirrhosis is becoming more common, reimbursement policies are improving, and cancer is becoming more common. These are the primary factors driving market expansion. The problems connected with ascites treatment, on the other hand, limit the market's expansion.

Market Dynamics

Cirrhosis' increased prevalence is projected to propel the industry forward. Cirrhotic ascites, for example, accounts for more than 75% of patients brought to hospital with ascites, according to a study published in the Canadian Journal of Gastroenterology and Hepatology in 2016. Cirrhosis of the liver is also shown to be common in the European region. According to a study published 2017, liver cirrhosis is the third most common cause of premature mortality in the UK when compared to other Western European countries, owing to rising alcohol intake and obesity. Because ascites is the most prevalent cirrhosis consequence that leads to hospitalisation and the usage of healthcare resources, the malignant ascites treatment market is likely to grow throughout the forecast period as the prevalence of cirrhosis rises.